Koninklijke Philips (NYSE:PHG) Rating Increased to Strong-Buy at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Koninklijke Philips (NYSE:PHG) from a hold rating to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

PHG has been the topic of a number of other research reports. UBS Group upgraded shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a research report on Thursday, February 20th. BNP Paribas upgraded shares of Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research report on Tuesday, February 25th. Finally, StockNews.com upgraded shares of Koninklijke Philips from a “hold” rating to a “buy” rating in a research report on Saturday, March 8th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Koninklijke Philips has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Down 3.4 %

Shares of Koninklijke Philips stock opened at $25.88 on Tuesday. The company has a market cap of $24.32 billion, a price-to-earnings ratio of -30.80, a price-to-earnings-growth ratio of 0.82 and a beta of 0.78. The company’s 50 day moving average is $26.74 and its 200 day moving average is $27.77. Koninklijke Philips has a twelve month low of $19.10 and a twelve month high of $32.91. The company has a quick ratio of 0.74, a current ratio of 1.23 and a debt-to-equity ratio of 0.59.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Wednesday, February 19th. The technology company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). The company had revenue of $5.38 billion for the quarter, compared to the consensus estimate of $5.10 billion. Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. Research analysts anticipate that Koninklijke Philips will post 1.63 EPS for the current year.

Koninklijke Philips Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 13th will be issued a dividend of $0.886 per share. The ex-dividend date is Tuesday, May 13th. This represents a yield of 2.9%. Koninklijke Philips’s dividend payout ratio is currently -89.29%.

Institutional Trading of Koninklijke Philips

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Colonial Trust Co SC increased its holdings in Koninklijke Philips by 724.0% during the fourth quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company’s stock valued at $36,000 after buying an additional 1,238 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Koninklijke Philips in the third quarter worth $54,000. Farther Finance Advisors LLC increased its stake in shares of Koninklijke Philips by 37.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company’s stock worth $54,000 after purchasing an additional 582 shares in the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of Koninklijke Philips in the fourth quarter worth $55,000. Finally, Millstone Evans Group LLC purchased a new stake in shares of Koninklijke Philips in the fourth quarter worth $60,000. 13.67% of the stock is owned by hedge funds and other institutional investors.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.